comprehensive -WSS

comprehensive

author：leisure time 2025-09-06 04:12:59 - browse：5751

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Roivant's CEO is a star, but biotech's black hole persists

Wikipedia

WSS

Study on Amgen’s bispecific immunotherapy produces positive data

Cassava Sciences’ Alzheimer’s clinical trials should be halted

ADCs take center stage as promising cancer treatments

How AI can help patients find reliable information about doctors

Obesity now affects over 1 billion people worldwide, study finds

Clinical trials giant ICON acquires HumanFirst

hotspot

comprehensive

leisure time

At least 13 dead in Texas as scorching temps continue

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Activists slam private health insurers over coverage restrictions

ALS groups 'won't be played again' by the FDA, drug sponsors

Wildfire smoke exposes gaps in outdoor worker protections

Flu vaccine offering decent levels of protection this winter, new data show

Virginia high school admissions case could be legal follow

FDA does about

Hepatitis C has a cure — but many Americans still lack access to it

Why getting cancer drugs just got harder for rural patients

knowledge

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

FogPharma raises $145 million in rare Series E round

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Pfizer highlights cancer drugs it thinks could reignite investor interest

RSV vaccines may be linked to small increased risk of developing GBS

entertainment

Wikipedia

entertainment

entertainment